Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 490–502 | Cite as

Binge Alcohol Consumption Aggravates Oxidative Stress and Promotes Pathogenesis of NASH from Obesity-Induced Simple Steatosis

  • Takahiro Minato
  • Mikihiro Tsutsumi
  • Mutsumi Tsuchishima
  • Nobuhiko Hayashi
  • Takashi Saito
  • Yasuhiro Matsue
  • Nobuyuki Toshikuni
  • Tomiyasu Arisawa
  • Joseph George
Research Article

Abstract

The pathogenesis of nonalcoholic steatohepatitis (NASH) is a two-stage process in which steatosis is the “first hit” and an unknown “second hit.” We hypothesized that “a binge” could be a “second hit” to develop NASH from obesity-induced simple steatosis. Thirty-week-old male Otsuka Long-Evans Tokushima fatty (OLETF) rats were administered 10 mL of 10% ethanol orally for 5, 3, 2, and 1 d/wk for 3 consecutive weeks. As control, male Otsuka Long-Evans Tokushima (OLET) rats were administered the same amount of alcohol. Various biochemical parameters of obesity, steatosis and NASH were monitored in serum and liver specimens in untreated and ethanol-treated rats. The liver sections were evaluated for histopathological alterations of NASH and stained for cytochrome P-4502E1 (CYP2E1) and 4-hydroxy-nonenal (4-HNE). Simple steatosis, hyperinsulinemia, hyperglycemia, insulin resistance, hypertriglycemia and marked increases in hepatic CYP2E1 and 4-HNE were present in 30-wk-old untreated OLETF rats. Massive steatohepatitis with hepatocyte ballooning was observed in the livers of all OLETF rats treated with ethanol. Serum and hepatic triglyceride levels as well as tumor necrosis factor (TNF)-α mRNA were markedly increased in all ethanol-treated OLETF rats. Staining for CYP2E1 and 4-NHE demonstrated marked increases in the hepatic tissue of all the groups of OLETF rats treated with ethanol compared with OLET rats. Our data demonstrated that “a binge” serves as a “second hit” for development of NASH from obesity-induced simple steatosis through aggravation of oxidative stress. The enhanced levels of CYP2E1 and increased oxidative stress in obesity play a significant role in this process.

Notes

Acknowledgments

The authors thank Mr. Mitsuru Araya for assistance in animal experiments. This work was supported in part by a grant for specially promoted research from Kanazawa Medical University (SR2012-04) and by a grant from the Ministry of Health, Labor, and Welfare of Japan.

References

  1. 1.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 55:434–8.PubMedGoogle Scholar
  2. 2.
    Sanyal AJ. (2002) AGA technical review in nonalcoholic fatty liver disease. Gastroenterology. 123:1705–25.CrossRefPubMedGoogle Scholar
  3. 3.
    Younossi ZM. (1999) Nonalcoholic fatty liver disease. Curr. Gastroenterol. Rep. 1:57–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Teli MR, James OF, Burt AD, Bennett MK, Day CP. (1995) The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 22:1714–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Day CP, James OFW. (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology. 114:842–5.CrossRefGoogle Scholar
  6. 6.
    Browning JD, Horton JD. (2004) Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114:147–52.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Burt AD, Mutton A, Day CP. (1998) Diagnosis and interpretation of steatosis and steatohepatitis. Semin. Diagn. Pathol. 15:246–58.PubMedGoogle Scholar
  8. 8.
    Matteoni CA, et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 116:1413–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chitturi S, Farrell GC. (2001) Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver. Dis. 21:27–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Paschos P, Paletas K. (2009) Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 13:9–19.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. (2011) An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology. 54:2185–97.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Jaeschke H, et al. (2002) Mechanisms of hepatotoxicity. Toxicol. Sci. 65:166–76.CrossRefPubMedGoogle Scholar
  13. 13.
    Raucy JL, et al. (1991) Induction of cytochrome P450IIE1 in the obese overfed rat. Mol. Pharmacol. 39:275–80.PubMedGoogle Scholar
  14. 14.
    Leclercq IA, et al. (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105:1067–75.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fong DG, Nehra V, Lindor KD, Buchman AL. (2000) Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology. 32:3–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. (2008) Free Radic. Biol. Med. 44:723–38.CrossRefPubMedGoogle Scholar
  17. 17.
    Takahashi T, Lasker JM, Rosman AS, Lieber CS. (1993) Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology. 17:236–45.PubMedGoogle Scholar
  18. 18.
    Tsutsumi M, Lasker JM, Shimizu M, Rosman AS, Lieber CS. (1989) The intralobular distribution of ethanol-inducible P450IIE1 in rat and human liver. Hepatology. 10:437–46.CrossRefPubMedGoogle Scholar
  19. 19.
    Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. (2010) Role of alcohol metabolism in nonalcoholic steatohepatitis. PLoS One. 5:e9570.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Favreau LV, Malchoff DM, Mole JE, Schenkman JB. (1987) Responses to insulin by two forms of rat hepatic microsomal cytochrome P-450 that undergo major (RLM6) and minor (RLM5b) elevations in diabetes. J. Biol. Chem. 262:14319–26.PubMedGoogle Scholar
  21. 21.
    Gonzalez FJ. (2005) Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res. 569:101–10.CrossRefPubMedGoogle Scholar
  22. 22.
    Sato T, Asahi Y, Toide K, Nakayama N. (1995) Insulin resistance in skeletal muscle of the male Otsuka Long-Evans Tokushima Fatty rat, a new model of NIDDM. Diabetologia. 38:1033–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Rector RS, et al. (2008) Cessation of daily exercise dramatically alters precursors of hepatic steatosis in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. J. Physiol. 586:4241–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ota T, et al. (2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology. 132:282–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Moran TH, Bi S. (2006) Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: developmental aspects. Dev. Psychobiol. 48:360–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Institute of Laboratory Animal Resources; Commission on Life Sciences; National Research Council. (1996) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academy Press.Google Scholar
  27. 27.
    Theodorsen L, Stromme JH. (1976) Gammaglutamyl-3-carboxy-14-nitroanilide: the substrate of choice for routine determinations of gammaglutamyl-transferase activity in serum? Clin. Chim. Acta. 72:205–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Kayamori Y, Hatsuyama H, Tsujioka T, Nasu M, Katayama Y. (1999) Endpoint colorimetric method for assaying total cholesterol in serum with cholesterol dehydrogenase. Clin. Chem. 45:2158–63.PubMedGoogle Scholar
  29. 29.
    Bucolo G, David H. (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem. 19:476–82.PubMedGoogle Scholar
  30. 30.
    Fishman S, et al. (2007) Resistance to leptin action is the major determinant of hepatic triglyceride accumulation in vivo. FASEB J. 21:53–60.CrossRefPubMedGoogle Scholar
  31. 31.
    Kleiner DE, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–21.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Roth CL, et al. (2012) Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Tolllike receptor activation. Hepatology. 55:1103–11.CrossRefPubMedGoogle Scholar
  33. 33.
    Amidi F, et al. (2007) M-30 and 4HNE are sequestered in different aggresomes in the same hepatocytes. Exp. Mol. Pathol. 83:296–300.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hu KQ, et al. (2004) Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J. Hepatol. 40:147–54.CrossRefPubMedGoogle Scholar
  35. 35.
    Farrell GC, Larter CZ. (2006) Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43(2 Suppl 1):S99–112.CrossRefPubMedGoogle Scholar
  36. 36.
    Lieber CS, DeCarli LM. (1986) The feeding of ethanol in liquid diets. Alcohol Clin. Exp. Res. 10:550–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Tamura S, Shimomura I. (2005) Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 115:1139–42.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. (2002) Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 35:898–904.CrossRefPubMedGoogle Scholar
  39. 39.
    Tian C, et al. (2014) Long term intake of 0.1% ethanol decreases serum adiponectin by suppressing PPARy expression via p38 MAPK pathway. Food Chem. Toxicol. 65:329–34.CrossRefPubMedGoogle Scholar
  40. 40.
    Tang H, et al. (2012) Ethanol-induced oxidative stress via the CYP2E1 pathway disrupts adiponectin secretion from adipocytes. Alcohol Clin. Exp. Res. 36:214–22.CrossRefPubMedGoogle Scholar
  41. 41.
    Deng T, et al. (2011) A peroxisome proliferator-activated receptor gamma (PPARgamma)/PPARgamma coactivator 1beta autoregulatory loop in adipocyte mitochondrial function. J. Biol. Chem. 286:30723–31.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Moller DE. (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 11:212–7.CrossRefPubMedGoogle Scholar
  43. 43.
    Lin HZ, Yang SQ, Kujhada F, Ronnet G, Diehl AM. (2000) Metformin reverses fatty liver disease in obese, leptin deficient mice. Nat. Med. 6:998–1003.CrossRefGoogle Scholar
  44. 44.
    Valenti L, et al. (2002) Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology. 122:274–80.CrossRefPubMedGoogle Scholar
  45. 45.
    Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389:610–4.CrossRefGoogle Scholar
  46. 46.
    Carmiel-Haggai M, Cederbaum AI, Nieto N. (2003) Binge ethanol exposure increases liver injury in obese rats. Gastroenterology. 125:1818–33.CrossRefPubMedGoogle Scholar
  47. 47.
    Abdelmegeed MA, et al. (2013) CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic. Biol. Med. 65:1238–45.CrossRefPubMedGoogle Scholar
  48. 48.
    Dunn W, et al. (2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 57:384–91.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Dunn W, Xu R, Schwimmer JB. (2008) Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology. 47:1947–54.CrossRefPubMedGoogle Scholar
  50. 50.
    Cotrim HP, et al. (2009) Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients. Eur. J. Gastroenterol. Hepatol. 21:969–972.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Takahiro Minato
    • 1
  • Mikihiro Tsutsumi
    • 1
  • Mutsumi Tsuchishima
    • 1
  • Nobuhiko Hayashi
    • 1
  • Takashi Saito
    • 1
  • Yasuhiro Matsue
    • 1
  • Nobuyuki Toshikuni
    • 1
  • Tomiyasu Arisawa
    • 2
  • Joseph George
    • 1
  1. 1.Department of HepatologyKanazawa Medical UniversityUchinadaJapan
  2. 2.Department of GastroenterologyKanazawa Medical UniversityUchinadaJapan

Personalised recommendations